SAHA Patient: IV vs ORAL (200 mg/dose)



FIG. 1

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)



FIG. 2

SAHA Patients: ORAL /Cohort I (200 mg/dose)



FIG. 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)



FIG. 4


Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)
7-OS-400
8-OS-400
IV
ORAL
IV
ORAL
-
+
Markers
Pre
Post
Pre
15 min
2 hr
6 hr
Pre
Post
Pre
0 hr
2 hr
α–AcH3
Coomassie stain
12/19/01
9-OS-400
IV
ORAL
-
+
Markers
Pre
Post
Pre
2 hr
6 hr
α–AcH3
12/27/01
Coomassie stain

FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)



FIG. 6

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)



FIG. 7

SAHA Patients: ORAL/Cohort II (400 mg/dose)





FIG. 8

Oral 200 mg vs. 400 mg (Fasting)



Figure 9A

Oral 200 mg vs. 400 mg (no-fasting)



Figure 9B

IV 200 mg vs. 400 mg



Figure 9C

Apparent Half-life of the Oral Dose



■=200 mg group (n=3-5); □=400 mg group (n=5-10)

3/4/2003

Figure 10

AUC of the Oral Dose



■ =200 mg group (n=3-5); □ =400 mg group (n=5-10)

3/4/2003

Figure 11

Bioavailability



F ~ 48%

Figure 12